Senior Investigator, Lady Davis Institute
Associate Professor, McGill University
Division of Pulmonary Diseases, Department of Medicine, Jewish General Hospital
David Small is a recognized researcher in pulmonary medicine. His research focuses primarily on lung cancer, asthma, sleep disorders, and chronic obstructive pulmonary disease. His projects include the study of inflammatory markers and developing a prognostic index for lung cancer patients, and the role of exercise training in lung cancer patients as well as quality of life outcomes. Other research interests include the molecular signature of cancer and new targeted therapy for lung cancer patients. He is conducting academic projects to validate new methodology for testing EGFR and ALK mutations. He is also the principal investigator on many NCIC and pharmaceutical industry sponsored trials involving new targeted medicine investigation. To date he has published more than 50 articles in the above mentioned areas.
Major Research Activities
Dr. Small is leading a number of multi-centre clinical trials studying clinical and quality of life outcomes in patients with lung cancer. He has sought to elucidate the impact of known prognostic factors, such as smoking, age, and gender, as well as new inflammatory and genetic markers of the tumor. His work focuses on developing personalized treatment guidelines based on prognostic factors. Dr. Small is also a member of numerous hospital and McGill committees. He is also a reviewer of CHEST (the cardio-pulmonary and critical care journal). Dr. Small has been an active participant at numerous consultative meetings, advisory boards, and forums organized by pharmaceutical companies, as well as the American Society of Clinical Oncology (ASCO), the American Thoracic Society (ATS), and others.
Recent Publications
Gagnon, B., Abrahamowicz M., Small D.et
al. (2010). "Flexible modeling improves assessment of prognostic
value of C-reactive protein in advanced non-small cell lung cancer."
British journal of cancer 102(7): 1113-1122.
Cohen, V., Agulnik J. S., Small D. et
al. (2010). "Epidermal growth factor receptor mutations detected
by denaturing high-performance liquid chromatography in nonsmall cell
lung cancer: impact on response to therapy with epidermal growth
factor receptor-tyrosine kinase inhibitors." Cancer
116(18): 4309-4317.
Retornaz, F.,
Monette J., Small D. et al. (2008).
"Usefulness of frailty markers in the assessment of the health
and functional status of older cancer patients referred for
chemotherapy: a pilot study." J Gerontol A Biol Sci Med Sci
63(5): 518-522.